OXA-244-Producing Escherichia coli Isolates, a Challenge for Clinical Microbiology Laboratories - Institut Pasteur Accéder directement au contenu
Article Dans Une Revue Antimicrobial Agents and Chemotherapy Année : 2017

OXA-244-Producing Escherichia coli Isolates, a Challenge for Clinical Microbiology Laboratories

Résumé

OXA-244 is a single-point-mutant derivative of OXA-48 displaying reduced carbapenemase activity. Here, we report the microbiological features of seven OXA-244-producing Escherichia coli isolates. Only one isolate grew on ChromID Carba Smart medium (bioMérieux), but six of the seven isolates grew on ChromID extended-spectrum-β-lactamase (ESBL) medium (bioMérieux), as they coproduced an ESBL and/or a plasmid-encoded cephalosporinase. The production of a carbapenemase was detected in 57.1%, 71.4%, 71.4%, and 100% of the E. coli isolates using the Carba NP test, the Rapidec Carba NP test (bioMérieux), a matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) hydrolysis assay (Bruker), and the OXA-48 K-SeT assay (Coris BioConcept), respectively. Our results indicate that OXA-244-producing E. coli isolates are difficult to detect, which may lead to their silent spread.
Fichier principal
Vignette du fichier
Hoyos_et_al_2017.pdf (839.91 Ko) Télécharger le fichier

Dates et versions

pasteur-03107799 , version 1 (12-01-2021)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Yannick Hoyos-Mallecot, Thierry Naas, Rémy Bonnin, Rafael Patino, Philippe Glaser, et al.. OXA-244-Producing Escherichia coli Isolates, a Challenge for Clinical Microbiology Laboratories. Antimicrobial Agents and Chemotherapy, 2017, 61 (9), ⟨10.1128/AAC.00818-17⟩. ⟨pasteur-03107799⟩
58 Consultations
71 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More